Flexion Therapeutics Inc (NASDAQ:FLXN) has earned an average recommendation of “Buy” from the twelve ratings firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $99.11.

Several analysts recently issued reports on FLXN shares. Northland Securities restated a “buy” rating and set a $40.00 target price on shares of Flexion Therapeutics in a research report on Friday, November 10th. Wells Fargo & Co set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Royal Bank of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, October 29th. Needham & Company LLC lifted their price target on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 9th. Finally, Laidlaw reaffirmed a “buy” rating and set a $38.00 price target (up previously from $35.00) on shares of Flexion Therapeutics in a report on Tuesday, October 10th.

In related news, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now owns 35,395 shares of the company’s stock, valued at $835,322. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Neil Bodick bought 2,700 shares of the stock in a transaction dated Tuesday, November 21st. The stock was bought at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the acquisition, the insider now directly owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The disclosure for this purchase can be found here. 15.98% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in FLXN. Schwab Charles Investment Management Inc. lifted its holdings in shares of Flexion Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after buying an additional 513 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Flexion Therapeutics by 46.0% in the second quarter. JPMorgan Chase & Co. now owns 167,350 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after buying an additional 52,763 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Flexion Therapeutics by 37.4% in the second quarter. Wells Fargo & Company MN now owns 171,351 shares of the specialty pharmaceutical company’s stock worth $3,464,000 after buying an additional 46,634 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Flexion Therapeutics by 71.5% in the second quarter. Alliancebernstein L.P. now owns 44,600 shares of the specialty pharmaceutical company’s stock worth $902,000 after buying an additional 18,600 shares in the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of Flexion Therapeutics by 13.4% in the second quarter. Teachers Advisors LLC now owns 50,779 shares of the specialty pharmaceutical company’s stock worth $1,027,000 after buying an additional 5,983 shares in the last quarter. 73.21% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Flexion Therapeutics (FLXN) traded up $2.23 during midday trading on Tuesday, reaching $23.80. 1,004,566 shares of the company traded hands, compared to its average volume of 730,231. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. The company has a market capitalization of $893.47, a price-to-earnings ratio of -6.76 and a beta of 0.91. Flexion Therapeutics has a 12 month low of $16.51 and a 12 month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.09). analysts predict that Flexion Therapeutics will post -3.84 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics Inc (FLXN) Receives Average Recommendation of “Buy” from Brokerages” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/flexion-therapeutics-inc-flxn-receives-average-recommendation-of-buy-from-brokerages/1848947.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.